Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens

This trial is a single center, single arm, open label clinical study aimed at evaluating the efficacy and safety of the combination therapy of Disitamab Vedotin and trastuzumab in the treatment of advanced HER-2 positive gastric/gastroesophageal junction tumors

Trial Details

NCT ID
NCT06572319
Phase
PHASE1 / PHASE2
Sponsor
Zhejiang Cancer Hospital
Status
RECRUITING
Cancer Type
Gastroesophageal Junction (GEJ) Gastric Cancer
Interventions
  • Disitamab Vedotin(RC48) Plus Tratuzumab
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • 1\. Sign the informed consent form; 2.18-75 years old (including 18 years old, excluding 75 years old), gender not limited; 3. The pathological his…
  • Absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelets ≥ 90 × 109/L, or
  • hemoglobin ≥ 9g/dL;
  • ALT or AST levels without liver metastasis are less than 2.5 times the upper limit of the normal range; When liver metastasis occurs, ALT or AST is…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastroesophageal Junction (GEJ) Gastric Cancer Trials on Trialify →